Squamous cell carcinoma of head and neck
Conditions
Interventions
Treatment group :pembrolizumab 200 mg every 3 weeks
Sponsors
Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1.Patients with histologically and/or cytologically confirmed recurrent or metastatic head and neck squamous cell carcinoma 2.Primary tumor sites include the oral cavity, oropharynx, larynx, hypopharynx, nasal cavity, nasal sinuses, and unknown primary sites 3.Age =18 years 4.No prior immunotherapy 5.Selected treatment options include pembrolizumab monotherapy, or pembrolizumab in combination with chemotherapy, targeted therapy, or other treatments 6.The hospital has complete follow-up data for patients
Exclusion criteria
Exclusion criteria: 1.Vaccinated with a live vaccine within 30 days prior to enrollment 2.Diagnosed with immunodeficiency or received systemic steroid treatment or any other form of immunosuppressive therapy within 7 days prior to enrollment 3.Also participated in other clinical studies during this period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival (OS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment of Pembrolizumab Time (TOPT);Objective Response Rate (ORR);OS, TOPT, and ORR in different CPS statuses; | — |
Countries
China
Contacts
Public ContactJinming Yu
Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences
Outcome results
None listed